{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:04:22Z","timestamp":1788318262173,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clml.2024.08.004","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T01:58:05Z","timestamp":1723082285000},"page":"96-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Evolving Role of Checkpoint Inhibitors in Multiple Myeloma"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7618-0215","authenticated-orcid":false,"given":"Ritu","family":"Chakrabarti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Biran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.08.004_bib0001","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-017-0256-z","article-title":"Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice","volume":"5","author":"Jing","year":"2017","journal-title":"J Immuno Cancer"},{"issue":"8","key":"10.1016\/j.clml.2024.08.004_bib0002","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","article-title":"Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade","volume":"17","author":"Hallett","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.clml.2024.08.004_bib0003","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.15946","article-title":"Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study","volume":"186","author":"Mateos","year":"2019","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.clml.2024.08.004_bib0004","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.clml.2024.08.004_bib0005","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.08.004_bib0006","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1038\/s41467-020-17459-z","article-title":"Accelerated single cell seeding in relapsed multiple myeloma","volume":"11","author":"Landau","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2024.08.004_bib0007","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases\u2013elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1016\/j.clml.2024.08.004_bib0008","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1084\/jem.194.1.45","article-title":"A coordinated change in chemokine responsiveness guides plasma cell movements","volume":"194","author":"Hargreaves","year":"2001","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.clml.2024.08.004_bib0009","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.leu.2402717","article-title":"Expression and function of chemokine receptors in human multiple myeloma","volume":"17","author":"M\u00f6ller","year":"2003","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2024.08.004_bib0010","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/leu.2015.332","article-title":"In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by \u03b14\u03b21 cytoplasmic-binding proteins","volume":"30","author":"Mart\u00ednez-Moreno","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2024.08.004_bib0011","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1023\/A:1006715504719","article-title":"Significance of VLA-4-VCAM-1 interaction and CD44 for transendothelial invasion in a bone marrow metastatic myeloma model","volume":"17","author":"Okada","year":"1999","journal-title":"Clin Exp Metastasis"},{"issue":"7","key":"10.1016\/j.clml.2024.08.004_bib0012","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V84.7.2269.2269","article-title":"Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures","volume":"84","author":"Lokhorst","year":"1994","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.08.004_bib0013","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003975","article-title":"Tumor-associated macrophages in multiple myeloma: advances in biology and therapy","volume":"10","author":"Sun","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"13","key":"10.1016\/j.clml.2024.08.004_bib0014","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.3390\/cancers13133213","article-title":"Mechanisms of immune evasion in multiple myeloma: open questions and therapeutic opportunities","volume":"13","author":"Botta","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.clml.2024.08.004_bib0015","doi-asserted-by":"crossref","first-page":"6491","DOI":"10.3390\/jcm11216491","article-title":"Pathways of angiogenic and inflammatory cytokines in multiple myeloma: role in plasma cell clonal expansion and drug resistance","volume":"11","author":"Melaccio","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.clml.2024.08.004_bib0016","doi-asserted-by":"crossref","first-page":"1852517","DOI":"10.1155\/2017\/1852517","article-title":"Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma","volume":"2017","author":"Musolino","year":"2017","journal-title":"Mediators Inflamm."},{"issue":"6","key":"10.1016\/j.clml.2024.08.004_bib0017","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3390\/cancers13061353","article-title":"Immune system alterations in multiple myeloma: molecular mechanisms and therapeutic strategies to reverse immunosuppression","volume":"13","author":"D\u00edaz-Tejedor","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clml.2024.08.004_bib0018","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.08.004_bib0019","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood-2015-01-623975","article-title":"Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing","volume":"126","author":"Leone","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.clml.2024.08.004_bib0020","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.3389\/fimmu.2018.02204","article-title":"Checkpoint inhibition in myeloma: opportunities and challenges","volume":"9","author":"Costa","year":"2018","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.clml.2024.08.004_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139867","article-title":"PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy","volume":"10","author":"Sponaas","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clml.2024.08.004_bib0022","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/cei.13594","article-title":"Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1\/PD-L1 pathway in multiple myeloma","volume":"205","author":"Liu","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clml.2024.08.004_bib0023","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41419-023-06389-5","article-title":"Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks","volume":"15","author":"Meng","year":"2024","journal-title":"Cell Death Dis"},{"issue":"20","key":"10.1016\/j.clml.2024.08.004_bib0024","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"G\u00f6rg\u00fcn","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.clml.2024.08.004_bib0025","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s12185-020-02953-3","article-title":"Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients","volume":"112","author":"Takezako","year":"2020","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2024.08.004_bib0026","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/bjh.15888","article-title":"Phase 1b trial of pembrolizumab monotherapy for relapsed\/refractory multiple myeloma: k-013","volume":"186","author":"Ribrag","year":"2019","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.clml.2024.08.004_bib47","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","article-title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"130","author":"Badros","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.08.004_bib0029","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3390\/cancers13102452","article-title":"Efficacy and safety of durvalumab combined with daratumumab in daratumumab-refractory multiple myeloma patients","volume":"13","author":"Frerichs","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.08.004_bib0030","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2018-99-114960","article-title":"Atezolizumab in combination with daratumumab with or without lenalidomide or pomalidomide: a phase Ib study in patients with multiple myeloma","volume":"132","author":"Cho","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.004_bib0028","first-page":"1858","article-title":"Nivolumab for treatment of advanced, refractory, high-risk multiple myeloma","volume":"130","author":"Thanendrarajan","year":"2017","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2024.08.004_bib0031","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood-2019-124339","article-title":"Efficacy and safety of nivolumab combined with daratumumab with or without low-dose cyclophosphamide in relapsed\/refractory multiple myeloma; interim analysis of the phase 2 nivo-dara study","volume":"134","author":"Verkleij","year":"2019","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.08.004_bib0033","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1200\/JCO.2022.40.16_suppl.8018","article-title":"Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-4 Study","volume":"40","author":"Suvannasankha","year":"2022","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2024.08.004_bib0027","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2024.08.004_bib48","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.1838.1838","article-title":"First Interim Results of a Phase I\/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"126","author":"Efebera","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2024.08.004_bib0032","doi-asserted-by":"crossref","first-page":"10254","DOI":"10.1002\/cam4.5753","article-title":"Isatuximab in combination with cemiplimab in patients with relapsed\/refractory multiple myeloma: a phase 1\/2 study","volume":"12","author":"Lesokhin","year":"2023","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.clml.2024.08.004_bib49","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/bloodadvances.2022008460","article-title":"Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed\/refractory multiple myeloma","volume":"7","author":"Nishihori","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.clml.2024.08.004_bib0034","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(24)00105-4","article-title":"Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA","volume":"11","author":"Khan","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.08.004_bib0035","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clml.2022.10.006","article-title":"Cobimetinib alone and plus venetoclax with\/without atezolizumab in patients with relapsed\/refractory multiple myeloma","volume":"23","author":"Schjesvold","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8_Supplement","key":"10.1016\/j.clml.2024.08.004_bib0037","doi-asserted-by":"crossref","first-page":"CT262","DOI":"10.1158\/1538-7445.AM2023-CT262","article-title":"Madhav dhodapkar; abstract CT262: durable responses following anti-TIGIT (BMS-986207) and anti-LAG3 (BMS-980616) in combination with pomalidomide in relapsed myeloma: MMRF MyCheckpoint trial","volume":"83","author":"Hearn","year":"2023","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.clml.2024.08.004_bib0036","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.immuni.2022.03.013","article-title":"Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity","volume":"55","author":"Maruhashi","year":"2022","journal-title":"Immun"},{"issue":"12","key":"10.1016\/j.clml.2024.08.004_bib0038","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.3390\/cancers12123615","article-title":"Pembrolizumab as consolidation strategy in patients with multiple myeloma: results of the GEM-pembresid clinical trial","volume":"12","author":"Puig","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.clml.2024.08.004_bib0039","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26333","article-title":"Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma","volume":"96","author":"Biran","year":"2021","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.clml.2024.08.004_bib0040","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.bbmt.2019.04.005","article-title":"A phase 2 study of pembrolizumab during lymphodepletion after autologous hematopoietic cell transplantation for multiple myeloma","volume":"25","author":"D'Souza","year":"2019","journal-title":"Biol Bld Mar Trans"},{"issue":"5","key":"10.1016\/j.clml.2024.08.004_bib0041","first-page":"391","article-title":"Safety and efficacy of consolidation therapy with ipilimumab plus nivolumab after autologous stem cell transplantation","volume":"27","author":"Skarbnik","year":"2021","journal-title":"Trans Cell Ther"},{"key":"10.1016\/j.clml.2024.08.004_bib0042","doi-asserted-by":"crossref","unstructured":"Pirogova OV, Darskaya EI, Porunova VV. Nivolumab combined with autologous hematopoietic stem cell transplantation in multiple myeloma patients. 2019. Accessed: January 5, 2024. Availabe at: http:\/\/cttjournal.com\/en\/archive\/tom-8-nomer-3\/kratkie-soobshcheniya\/ispolzovanie-nivolumaba-v-kombinatsii-s-autologichnoy-transplantatsiey-gemopoeticheskikh-stvolovykh-\/.","DOI":"10.1097\/01.HS9.0000563860.35670.9c"},{"key":"10.1016\/j.clml.2024.08.004_bib0043","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-024-01030-w","article-title":"Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk","volume":"14","author":"Callander","year":"2024","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.clml.2024.08.004_bib0044","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.08.004_bib0045","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2024.08.004_bib0046","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.4049\/jimmunol.1202005","article-title":"Programmed death receptor-1\/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma","volume":"190","author":"Kearl","year":"2013","journal-title":"J Immunol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T10:59:23Z","timestamp":1738061963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2152265024002933"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.08.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Evolving Role of Checkpoint Inhibitors in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}